Compound
TB-500 and LKKTETQ: Understanding the Thymosin β4 Fragment
LKKTETQ names one fragment. Ac-LKKTETQ names another. A proposed mechanism is not a healing proof.
Residues 17–23
Inside thymosin β4, residues 17–23 form a short window: leucine, lysine, lysine, threonine, glutamate, threonine, glutamine. In one-letter code that is LKKTETQ. That window is the sequence origin of both the non-acetylated fragment and TB-500.1,3
Tβ4 remains 43 amino acids long. Cutting out seven residues produces a new object. It does not produce a compact version of the same drug.7
What LKKTETQ names
Studied moleculeNon-acetylated fragment
LKKTETQ
A heptapeptide corresponding to residues 17–23 of thymosin β4. In the wound studies most often cited, it was evaluated without N-terminal acetylation.2
Philp 2003 used that non-acetylated heptapeptide, together with full-length thymosin β4, in mouse models. FDA classifies it as a study of the non-acetylated fragment, not as a TB-500 study.2,1
Actin-binding region
The Tβ4 literature attributes to a six-amino-acid stretch, LKKTET, the actin-binding region. The proposal is that, by binding G-actin and not F-actin, that region participates in the monomer buffer that feeds filaments.3,1
That is a mechanism hypothesis about a region. It is not a demonstration that the heptapeptide, acetylated or not, reproduces every activity of the 43-residue peptide. The review that summarizes those activities leaves open whether actin binding explains angiogenesis or repair.3
Non-acetylated versus acetylated
Three objects that share letters and do not share a record.
| Object | Conceptual sequence | What has been studied |
|---|---|---|
| Non-acetylated fragment | LKKTETQ | Dermal wound work in mice (Philp 2003) |
| TB-500 | Ac-LKKTETQ | Analytical identity; free-base in-vitro scratch assay |
| Metabolite cited by FDA | N-acetylated LKKTE | A small effect in the same scratch assay |
Studied moleculeTB-500 / Ac-LKKTETQ
Esposito identified Ac-LKKTETQ in material called TB-500. That N-terminal acetylation is the difference that the name LKKTETQ, written without Ac-, does not communicate.5
Why acetylation matters
N-terminal acetylation of peptides and proteins is irreversible in the usual chemical sense of that modification: it changes charge, hydrophobicity, and the effective size of the chain. It can alter lifespan, folding, and binding.4,1
FDA draws the editorial consequence this page must repeat: the pharmacological profile of non-acetylated LKKTETQ cannot be directly extrapolated to TB-500. That sentence is not a physical-chemistry aside. It is the reason Philp 2003 does not enter the direct-evidence column.1
Proposed G-actin mechanism
The proposed model says LKKTETQ might retain some of Tβ4’s capacity to sequester G-actin and thereby influence cell shape, movement, and communication. It is a model. It remains to be determined, in the very text FDA cites, whether that binding explains the activities attributed to the heptapeptide.3,1
A cellular mechanism is not a claim of tendon repair in a person, not a protocol, and not proof that the acetylated fragment does what the non-acetylated fragment did. Biological plausibility explains why someone studied that sequence window. It does not authorize selling a mouse result as if it were TB-500.
It also does not authorize treating the N-acetylated LKKTE metabolite as if it restored the parent compound. A metabolite is a different object. If only the metabolite moves the needle in a fibroblast scratch, that splits the story; it does not unify it.6
Limits of the mechanism evidence
- The mechanism is discussed for Tβ4 and short regions, not for a TB-500 clinical program.
- Philp 2003 is an animal model of non-acetylated LKKTETQ and of Tβ4, not of Ac-LKKTETQ.
- The in-vitro scratch assay of TB-500 free base did not show a significant difference versus vehicle under the described conditions.
- A different metabolite does not restore the parent compound as if they were one.
Rahaman 2024 and FDA’s summary make the point: under the assay conditions, the free base did not close the wound to a significant degree and the N-acetylated LKKTE metabolite showed a small effect. Fragment, metabolite, and full-length peptide do not add up into one “repair” story.6,1
FDA’s warning about extrapolation
The Agency does not stop at defining the sequence. It says that extrapolating the non-acetylated fragment to TB-500 is inappropriate because acetylation changes properties that matter for peptide behavior. This page does not turn that warning into a verdict that TB-500 “does not act.” It turns the warning into a reading rule.1
The rule is simple to apply. If the methods name LKKTETQ and do not name the acetyl group, the result stays in the non-acetylated-fragment column. If the methods name Ac-LKKTETQ or TB-500 with that identity, the result may enter the TB-500 column. If the methods name 43-residue thymosin β4, the result enters neither fragment column.1,2,5
That rule does not deny that the three molecules can be discussed in the same laboratory. It denies that they can be discussed as if they were one.
References
Regulatory source
Studied moleculeTB-500 / Ac-LKKTETQ
July 23-24, 2026 Pharmacy Compounding Advisory Committee — FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate)FDA PCAC briefing. 2026
Regulatory source — United States
FDA staff evaluation for a 503A nomination. The Agency stated that it did not identify clinical studies or human exposure data using TB-500. Not a final rule and not drug approval.
Preclinical study — animal
Studied moleculeNon-acetylated fragment
Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK.
Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice.Wound Repair Regen. 2003;11(1):19-24. 2003
DOI 10.1046/j.1524-475x.2003.11105.x
Mouse study of full-length thymosin β4 and the non-acetylated heptapeptide LKKTETQ. Not a TB-500 study and not a human trial.
Scientific review
Studied moleculeFull-length thymosin β4
Sosne G, Qiu P, Goldstein AL, Wheater M.
Biological activities of thymosin beta4 defined by active sites in short peptide sequences.Expert Opin Biol Ther. 2010;10(4):537-550. 2010
Review of proposed active sites within full-length thymosin β4, including the actin-binding region. Not a TB-500 clinical study.
Scientific reference
Ree R, Varland S, Arnesen T.
Spotlight on protein N-terminal acetylation.Exp Mol Med. 2018;50(7):1-13. 2018
General biochemistry of N-terminal acetylation. Cited for why acetylation can change peptide properties, not as TB-500 efficacy evidence.
Analytical / anti-doping research
Studied moleculeTB-500 / Ac-LKKTETQ
Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P.
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.Drug Test Anal. 2012;4(9):733-738. 2012
Analytical identification of Ac-LKKTETQ in TB-500 for anti-doping purposes. Not a human clinical efficacy study.
In-vitro study
Studied moleculeTB-500 / Ac-LKKTETQ
Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ, Kwon OS.
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. 2024
DOI 10.1016/j.jchromb.2024.124033
In-vitro fibroblast scratch assay and analytical work. FDA summarized that TB-500 free base did not differ significantly from vehicle under the tested conditions. Not a human clinical study. Metabolite detection details are not used here as anti-doping operational information.
Regulatory source
Studied moleculeFull-length thymosin β4
Thymosin beta-4 — FDA Global Substance Registration System (UNII 549LM7U24W)FDA GSRS. 2026
Regulatory source — United States
Identity record for full-length thymosin β4. Distinct from the TB-500 UNII. Registration is not approval.
Peptra Health materials are for laboratory research use only. This article is educational and is not medical advice.
Related research
- What Is TB-500? Structure, Sequence & Evidence
TB-500 is an N-acetylated synthetic heptapeptide. Related to thymosin β4 is not the same as being thymosin β4.
- TB-500, Wounds & Tendons: What Evidence Is Actually Direct
A wound literature exists in this family. Almost none of the usual citations is a direct TB-500 trial.
Related documentation
Note on nomenclature: the commercial name TB-500 has been used for materials with different molecular descriptions. A lot’s analytical documentation must be reviewed separately and does not automatically imply equivalence with the molecular identity described in the literature or in regulatory documents.